Compile Data Set for Download or QSAR
Report error Found 25 Enz. Inhib. hit(s) with all data for entry = 50018674
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198005(10,16-bis(hydroxymethyl)-22-[(1E)-3-(1H-imidazol-1...)
Affinity DataIC50: 3nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198018(10,16-bis(hydroxymethyl)-4,14,18-triazaheptacyclo[...)
Affinity DataIC50: 3nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50059889(3-methoxy-2-methyl-4-methylamino-(2S,3S,4S,6R)-29-...)
Affinity DataIC50: 6nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198014(16-(hydroxymethyl)-22-[(1E)-3-(1H-imidazol-1-yl)pr...)
Affinity DataIC50: 11nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198020(16,16-bis(hydroxymethyl)-4,14,18-triazaheptacyclo[...)
Affinity DataIC50: 13.5nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198025(10,16,22-tris(hydroxymethyl)-4,14,18-triazaheptacy...)
Affinity DataIC50: 14nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198023(22-bromo-16-(hydroxymethyl)-3-oxo-4,14,18-triazahe...)
Affinity DataIC50: 15nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198004(16-(hydroxymethyl)-4,14,18-triazaheptacyclo[12.10....)
Affinity DataIC50: 17.5nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198006(22-bromo-16-(hydroxymethyl)-4,14,18-triazaheptacyc...)
Affinity DataIC50: 23.5nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198009(16-hydroxy-16-(hydroxymethyl)-4,14,18-triazaheptac...)
Affinity DataIC50: 27nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198019(22-[(1E)-3-(4,5-dihydro-1H-imidazol-2-ylamino)prop...)
Affinity DataIC50: 31nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198017(16-(1,3-dihydroxypropan-2-ylidene)-4,14,18-triazah...)
Affinity DataIC50: 36nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198015(22-bromo-16-(hydroxymethyl)-10-[(propan-2-yloxy)me...)
Affinity DataIC50: 70nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198010(16-methylidene-4,14,18-triazaheptacyclo[12.10.2.0^...)
Affinity DataIC50: 72nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198022(16-(hydroxymethyl)-10-[(propan-2-yloxy)methyl]-4,1...)
Affinity DataIC50: 80nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198024(16-(hydroxymethyl)-22-[(E)-2-(1H-imidazol-1-yl)eth...)
Affinity DataIC50: 109nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198012(16-hydroxy-4,14,18-triazaheptacyclo[12.10.2.0^{2,6...)
Affinity DataIC50: 142nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198016((2E)-N-[3-(dimethylamino)propyl]-3-[16-(hydroxymet...)
Affinity DataIC50: 237nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198008(10-[(dimethylamino)methyl]-16-(hydroxymethyl)-4,14...)
Affinity DataIC50: 250nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198021(16-(hydroxymethyl)-22-[(E)-2-(pyridin-2-yl)ethenyl...)
Affinity DataIC50: 354nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198002(16-(hydroxymethyl)-22-[(E)-2-(4-methyl-1,3-thiazol...)
Affinity DataIC50: 592nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198003((2E)-3-[16-(hydroxymethyl)-5-oxo-4,14,18-triazahep...)
Affinity DataIC50: 686nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198013(16-(hydroxymethyl)-10,22-bis[(propan-2-yloxy)methy...)
Affinity DataIC50: 1.05E+3nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198007(22-bromo-16-(hydroxymethyl)-10-(morpholin-4-ylmeth...)
Affinity DataIC50: 3.13E+3nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Johnson & Johnson Pharmaceutical Research and Development

Curated by ChEMBL
LigandPNGBDBM50198011(16-(hydroxymethyl)-10,22-bis(morpholin-4-ylmethyl)...)
Affinity DataIC50: 5.00E+3nMAssay Description:Inhibition of JAK3 expressed in Sf21 cellsMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed